Characteristics of HPC(A) product obtained from a donor with SARS-CoV-2 infection and outcome of autologous transplant

• HPC(A) product collected during acute, minimally symptomatic SARS-CoV-2 infection tested negative for viral RNA by RT-PCR, suggesting low risk of product viremia. • Autologous stem cell transplant using this product was successful, with engraftment and recovery, indicating that transplantation may be feasible in such scenarios. • Donor screening questionnaires may miss minimally symptomatic Covid-19 cases, highlighting the need for objective testing and careful risk assessment. • This case provides evidence that HPC(A) collection during acute Covid-19 infection may be safe, but larger studies are needed to confirm outcomes.